Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Depreciation and Depletion: 2010-2024

Historic Depreciation and Depletion for Ligand Pharmaceuticals (LGND) over the last 15 years, with Dec 2024 value amounting to $2.3 million.

  • Ligand Pharmaceuticals' Depreciation and Depletion fell 76.63% to $172,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 33.47%. This contributed to the annual value of $2.3 million for FY2024, which is 20.69% down from last year.
  • Ligand Pharmaceuticals' Depreciation and Depletion amounted to $2.3 million in FY2024, which was down 20.69% from $2.9 million recorded in FY2023.
  • Ligand Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $3.8 million during FY2022, with a 5-year trough of $1.5 million in FY2020.
  • In the last 3 years, Ligand Pharmaceuticals' Depreciation and Depletion had a median value of $2.9 million in 2023 and averaged $3.0 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Depreciation and Depletion soared by 60.00% in 2021, and later fell by 23.68% in 2023.
  • Ligand Pharmaceuticals' Depreciation and Depletion (Yearly) stood at $1.5 million in 2020, then spiked by 60.00% to $2.4 million in 2021, then soared by 58.33% to $3.8 million in 2022, then fell by 23.68% to $2.9 million in 2023, then fell by 20.69% to $2.3 million in 2024.